Fact CheckerSign in

NCT06215131Completed

Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease

Feasibility of Immersive Virtual Reality Dietician Program in Patients With Metabolic-dysfunction Associated Steatotic Liver Disease

Source: ClinicalTrials.gov · Last updated 31 Oct 2025

Brief summary (registry, in English)

Metabolic-dysfunction associated steatotic liver disease, often referred to as "fatty liver disease", is a leading cause of liver failure. Dietary weight loss is a cornerstone of treating fatty liver disease, but access to traditional in-person nutritional education is often limited by cost, availability, and transportation. Immersive virtual reality (iVR) has the potential to not only overcome these barriers, but also provide an interactive learning experience, such as measuring and preparing foods. Therefore, the investigators have created and validated an iVR dietician program known as the Immersive Virtual Alimentation and Nutrition (IVAN) using evidence-informed practices from the Academy of Nutrition and Dietetics. The goal of this project is to translate the IVAN program from human and patient research to practice and community research. The investigators plan to accomplish this by performing a randomized clinical trial evaluating the effect of the IVAN program in combination with synchronous audio/video dietary counseling on self-reported dietary intake and weight compared to in-person counseling. Concurrently, the investigators will provide a survey assessing implementation outcomes to both groups as well as the dietician at each study visit, and crossover the intervention at study completion so all participants assess the IVAN program. Additionally, the investigators will have clinic health care providers experience the IVAN program and assess implementation outcomes.

Status (registry)
Completed
Study type
Interventional
Enrollment
20 (actual)
First submitted
10 Jan 2024
Start date
1 Jul 2024
Primary completion date
23 Sept 2025
Lead sponsor
Milton S. Hershey Medical Center
NCT number
NCT06215131

What you commit to

  • Study type: Interventional
  • Participants enrolled: 20
  • From 1 Jul 2024 to the primary completion date, 23 Sept 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Other causes of hepatic steatosis or chronic liver disease
  • Severe medical/psychiatric comorbidities at the study PI's discretion

Other

  • Inability to provide informed consent
  • Institutionalized/prisoner
  • Pregnant

Who the study is looking for

  • Adults age \>18 years
  • MASLD identified on imaging
  • Possession of a smartphone

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Penn State College of Medicine
Coordinator of this site? Confirm its status
HersheyUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.